Capital Fund Management S.A. Invests $1.20 Million in Myriad Genetics, Inc. (NASDAQ:MYGN)

Capital Fund Management S.A. bought a new position in shares of Myriad Genetics, Inc. (NASDAQ:MYGN - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 87,555 shares of the company's stock, valued at approximately $1,200,000. Capital Fund Management S.A. owned about 0.10% of Myriad Genetics at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in MYGN. KBC Group NV boosted its stake in Myriad Genetics by 132.8% in the 4th quarter. KBC Group NV now owns 5,845 shares of the company's stock valued at $80,000 after purchasing an additional 3,334 shares during the period. Inspire Advisors LLC grew its position in Myriad Genetics by 48.1% in the fourth quarter. Inspire Advisors LLC now owns 11,226 shares of the company's stock valued at $154,000 after acquiring an additional 3,644 shares during the last quarter. E Fund Management Co. Ltd. acquired a new position in Myriad Genetics during the 4th quarter worth approximately $161,000. Entropy Technologies LP bought a new position in shares of Myriad Genetics in the 4th quarter valued at $178,000. Finally, Polymer Capital Management US LLC acquired a new stake in shares of Myriad Genetics during the fourth quarter valued at about $179,000. Institutional investors and hedge funds own 99.02% of the company's stock.

Myriad Genetics Trading Down 3.6 %

Shares of MYGN traded down $0.28 during mid-day trading on Monday, reaching $7.37. 110,735 shares of the company's stock traded hands, compared to its average volume of 907,601. The stock has a market cap of $678.84 million, a P/E ratio of -5.67 and a beta of 1.87. Myriad Genetics, Inc. has a 12 month low of $7.35 and a 12 month high of $29.30. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.90 and a quick ratio of 1.73. The stock's 50-day moving average is $10.24 and its two-hundred day moving average is $14.24.

Myriad Genetics (NASDAQ:MYGN - Get Free Report) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.03 by ($0.12). The firm had revenue of $210.60 million during the quarter, compared to analysts' expectations of $210.35 million. Myriad Genetics had a negative return on equity of 4.51% and a negative net margin of 14.09%. During the same period in the previous year, the firm earned ($0.12) EPS. Research analysts forecast that Myriad Genetics, Inc. will post -0.3 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have weighed in on MYGN. Bank of America decreased their price target on Myriad Genetics from $13.00 to $11.00 and set an "underperform" rating for the company in a report on Monday, March 3rd. Raymond James reiterated an "outperform" rating and set a $19.00 price objective (down from $27.00) on shares of Myriad Genetics in a report on Tuesday, February 25th. StockNews.com upgraded Myriad Genetics from a "hold" rating to a "buy" rating in a research note on Thursday, April 10th. Scotiabank reduced their target price on Myriad Genetics from $24.00 to $20.00 and set a "sector outperform" rating for the company in a report on Tuesday, April 1st. Finally, Guggenheim downgraded shares of Myriad Genetics from a "buy" rating to a "neutral" rating in a report on Wednesday, April 9th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $20.61.

Myriad Genetics Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.